Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment
This study is currently recruiting patients.
Sponsored by: | H. Lee Moffitt Cancer Center and Research Institute |
---|---|
Information provided by: | National Cancer Institute (NCI) |
Purpose
RATIONALE: Cyproheptadine and megestrol may improve appetite and help prevent weight loss in children with cancer.
PURPOSE: Clinical trial to study the effectiveness of cyproheptadine and megestrol in improving appetite and preventing weight loss in children who have cachexia caused by cancer or cancer treatment.
Condition | Treatment or Intervention |
---|---|
Cachexia childhood Hodgkin's lymphoma childhood brain tumor childhood non-Hodgkin's lymphoma childhood solid tumor hematopoietic and lymphoid cancer |
Drug: cyproheptadine Drug: megestrol Procedure: anticachectic therapy Procedure: nutritional support Procedure: supportive care/therapy |
MedlinePlus related topics: Blood and Blood Disorders; Cancer; Cancer Alternative Therapy; Hodgkin's Disease; Lymphoma
Study Type: Interventional
Study Design: Treatment
Official Title: Study of Cyproheptadine and Megestrol in Preventing Further Weight Loss In Children with Cancer or Cancer Treatment-Related Cachexia
OBJECTIVES:
OUTLINE: Patients receive oral cyproheptadine twice daily for 4 weeks in the absence of unacceptable weight loss or toxicity. Patients that present with weight loss after 4 weeks receive oral megestrol daily for 4 weeks in the absence of unacceptable weight loss or toxicity.
Patients are followed at 4 weeks.
PROJECTED ACCRUAL: A total of 70 patients will be accrued for this study.
Eligibility
Ages Eligible for Study: 2 Years - 20 Years, Genders Eligible for Study: Both
Criteria
DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS: Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Cardiovascular
Other
PRIOR CONCURRENT THERAPY: Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
Other
Location and Contact Information
More Information
Clinical trial summary from the National Cancer Institute's PDQ® database
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |